Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
survival 79% (72-86) and 94% (90-98).Immediate androgen suppression with an LHRH analogue given during and for 3 years after external irradiation improves disease-free and overall survival of patients with locally advanced prostatecancer. (...) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostatecancer (an EORTC study): a phase III randomised trial. We did a randomised phase III trial comparing external irradiation alone and external irradiation combined with an analogue of luteinising-hormone releasing hormone (LHRH) to investigate the added value of long-term androgen suppression in locally advanced prostate cancer.Between 1987 and 1995, 415 patients were randomly
2002LancetControlled trial quality: predicted high
A randomized trial comparing radical prostatectomy with watchful waiting in early prostatecancer. Radical prostatectomy is widely used in the treatment of early prostatecancer. The possible survival benefit of this treatment, however, is unclear. We conducted a randomized trial to address this question.From October 1989 through February 1999, 695 men with newly diagnosed prostatecancer in International Union against Cancer clinical stage T1b, T1c, or T2 were randomly assigned to watchful (...) waiting or radical prostatectomy. We achieved complete follow-up through the year 2000 with blinded evaluation of causes of death. The primary end point was death due to prostatecancer, and the secondary end points were overall mortality, metastasis-free survival, and local progression.During a median of 6.2 years of follow-up, 62 men in the watchful-waiting group and 53 in the radical-prostatectomy group died (P=0.31). Death due to prostatecancer occurred in 31 of 348 of those assigned to watchful
Early versus deferred androgen suppression in the treatment of advanced prostaticcancer. Prostatecancer is a leading cause of cancer death in men. Treatment goals for men with advanced prostatecancer include prolonging survival, preventing or delaying symptoms due to disease progression, improving and maintaining quality of life, reducing treatment related morbidity. Androgen suppression therapy is considered a mainstay of treatment for men with advanced prostatecancer. However (...) , EMBASE, CancerLIT, Cochrane Library, VA Cochrane ProstateDisease register) and by reviewing bibliographies including those of the Blue Cross and Blue Shield Association Technology Evaluation Center/Evidence-based Practice Center of the Agency for Healthcare Research and Quality (BCBS/TEC-AHRQ) report No.4.All published randomized trials were eligible for inclusion provided they: randomized men with advanced prostatecancer to early versus deferred androgen suppression; reported overall, progression
[The effectiveness and safety of different forms of treating prostatecancer] La efectividad y seguridad de los distintos tratamientos del cancer de prostata [The effectiveness and safety of different forms of treating prostatecancer] La efectividad y seguridad de los distintos tratamientos del cancer de prostata [The effectiveness and safety of different forms of treating prostatecancer] Rueda J R, Lecumberri D, Casquero F, Pereira G, Escobal V Citation Rueda J R, Lecumberri D, Casquero F (...) , Pereira G, Escobal V. La efectividad y seguridad de los distintos tratamientos del cancer de prostata. [The effectiveness and safety of different forms of treating prostatecancer] Vitoria-Gasteiz: Basque Office for Health Technology Assessment (OSTEBA). D-02-06. 2002 Authors' objectives
This review aims to determine the effectiveness and safety of the different therapeutic options available for prostatecancer.
Final publication URL Indexing Status Subject indexing assigned by CRD MeSH
Screening for prostatecancer Screening for prostatecancer Screening for prostatecancer Harris R, Lohr K N, Beck R, Fink K, Godley P, Bunton A J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Harris R, Lohr K N, Beck R, Fink K, Godley P, Bunton A J. Screening for prostatecancer. Rockville: Agency for Healthcare Research and Quality (...) (AHRQ). Preventive Services Task Force Systematic Evidence Review No. 16. 2002 Authors' objectives To examine the evidence of the benefits and harms of screening and earlier treatment in reducing prostatecancer mortality and to assist the US Preventive Services Task Force in making recommendations on this topic. Authors' conclusions We are unable to determine the net benefit of screening because we cannot establish the presence and, if present, the magnitude of benefit from screening. We can
conclusions The effectiveness analysis showed that positive bone scans were quite rare in patients with serum PSA levels less than or equal to 10 ng/mL, especially those patients with a tumour of Gleason Grade less than or equal to 2. Modelling A decision tree model was constructed in order to simulate the natural history and clinical management (mainly based on monitoring) of a cohort of patients with newly diagnosed prostatecancer. Cumulative costs and expected disease-specific survival rates were (...) , Ichihara K, Yonese J, Koizumi M, Nakashima J, Fujii H. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostatecarcinoma? A multicenter retrospective study in Japan. Cancer 2002; 94(4): 964-972 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Aged, 80 and over; Biopsy, Needle; Bone Neoplasms /diagnosis /radionuclide imaging /secondary; Carcinoma /pathology; Decision Making; Humans; Male; Middle Aged
for 1 month, starting 1 week before the first dose of goserelin. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with histologically proven locally advanced prostatecancer (cT3-4, N0-2, M0), according to the tumour-node-metastasis classification system of the International Union against Cancer. The patients were younger than 80 years of age and had not undergone any earlier treatment for prostatecancer (...) . Patients with a prior malignantdisease (except for treated basal-cell carcinoma of the skin) and those with evidence of distant metastases were excluded. Setting The setting was a hospital. The economic study was carried out in France. Dates to which data relate The effectiveness evidence and resource use data were derived from a study published in 1997 (see Other Publications of Related Interest). The data were collected between 1987 and 1995. The price year was 1998. Source of effectiveness data
Local staging of prostatecancer using magnetic resonance imaging: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Treating prostatecancer with brachytherapy Treating prostatecancer with brachytherapy Treating prostatecancer with brachytherapy Johansen T B, Dahl O, Heikkila R, Hoisaeter P A, Klepp O, Olsen D R, Waehre H Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Johansen T B, Dahl O, Heikkila R, Hoisaeter P A, Klepp O, Olsen D R, Waehre H (...) . Treating prostatecancer with brachytherapy. Oslo: The Norwegian Knowledge Centre for the Health Services (NOKC) 2002 Authors' objectives This report assesses the clinical effectiveness and cost effectiveness of prostate brachytherapy compared with radical prostatectomy, external beam radiation or watchful waiting. Authors' conclusions overall or cancer free survival: In most cases prostatecancer progress slowly; 5-year survival for localised prostatecancer is around 80%. None of the included studies
The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 prostatecancer The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 prostatecancer The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 prostatecancer Brundage M, Lukka H, Crook J, Warde P, Bauman G, Catton C, Markman B R, Charette M, Genitourinary CancerDisease Site Group CRD summary This review evaluated the effects of conformal radiotherapy (CR (...) the benefits of dose escalation when CR is used. Funding Cancer Care Ontario; Ontario Ministry of Health and Long-term Care. Bibliographic details Brundage M, Lukka H, Crook J, Warde P, Bauman G, Catton C, Markman B R, Charette M, Genitourinary CancerDisease Site Group. The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 prostatecancer. Cancer Care Ontario Practice Guidelines Initiative 2002. Available at: Accessed April, 2014 This paper is produced by Cancer Care Ontario
Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostatecancer screening Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostatecancer screening Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostatecancer screening Ellison L, Cheli C D, Bright S, Veltri R W, Partin A W Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of prostate-specific antigen (PSA) for population-based prostatecancer screening. Five strategies were identified. These were total PSA (tPSA) 4.0 ng/mg, free PSA/tPSA (f/tPSA), and complexed PSA (cPSA) 3.8, 3.4, and 3.0 ng/mg. Type of intervention Screening. Economic study
Exposure to ultraviolet radiation: association with susceptibility and age at presentation with prostatecancer. A positive association between latitude and prostatecancer mortality has been interpreted to indicate that ultraviolet radiation (UVR) protects against development of this cancer. We aimed to examine this hypothesis. We compared exposure between 210 cases and 155 controls. Childhood sunburn (odds ratio 0.18, 95% CI 0.08-0.38), regular foreign holidays(0.41, 0.25-0.68), sunbathing (...) score (0.83, 0.76-0.89), and low exposure to UVR (3.03, 1.59-5.78) were associated with development of prostatecancer. Furthermore, cases with low UVR exposure developed cancer at a younger median age (67.7 years, IQR 61.5-74.6) than cases with higher exposure (72.1 years, 67.5-76.4); p=0.006. These findings are compatible with UVR having a protective role against prostatecancer.
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Prostatecarcinoma is linked to osteoblastic metastasis. We therefore investigated the value of bone-targeted consolidation therapy in selected patients with advanced androgen-independent carcinoma of the prostate.103 patients received induction chemotherapy, consisting of ketoconazole and doxorubicin alternating with estramustine and vinblastine. After two or three cycles (...) with stable or responding advanced androgen-independent carcinoma of the prostate after induction chemotherapy, improved overall survival.
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostatecancer. Treatment with a gonadotropin-releasing hormone agonist decreases bone mineral density and increases the risk of fracture in men with prostatecancer. We conducted a controlled study of the prevention of osteoporosis in men undergoing treatment with a gonadotropin-releasing hormone agonist.In a 48-week, open-label study, we randomly assigned 47 men with advanced or recurrent prostatecancer and no bone (...) = 0.003), total hip (P=0.005), and trabecular bone of the lumbar spine (P=0.02).Pamidronate prevents bone loss in the hip and lumbar spine in men receiving treatment for prostatecancer with a gonadotropin-releasing hormone agonist.
and Cancerlit were searched from 1988 to April 1999 using the terms 'prostatecancer', 'prostateneoplasm', 'brachytherapy', 'seed implant', 'interstitial radiotherapy', 'practice guideline', 'meta-analysis', 'randomized clinical trial' and 'clinical trial'. Studies reported as abstracts were excluded from the review. The web-based version of this review reported that it is currently being updated using the following searches: MEDLINE from April 1999 to May 2001; Cancerlit from April 1999 to March 2001 (...) Systematic overview of the evidence for brachytherapy in clinically localized prostatecancer Systematic overview of the evidence for brachytherapy in clinically localized prostatecancer Systematic overview of the evidence for brachytherapy in clinically localized prostatecancer Crook J, Lukka H, Klotz L, Bestic N, Johnston M Authors' objectives To examine the role of brachytherapy (permanent seed implantation) in treating clinically localised (T1 and T2) prostatecancer. Searching MEDLINE
prostatecancer. Searching MEDLINE and Cancerlit were searched from 1966 to 2000 using the combined subject headings of 'prostateneoplasms', 'radiotherapy', 'biochemical control' and 'dose'. In addition, the citation lists of relevant articles were examined, and relevant journals published in 2000 were manually reviewed. Study selection Study designs of evaluations included in the review There was no stated restriction on the study design. Of the included studies, 2 were randomised trials (...) studies used non-standard units when reporting the dose. RT was delivered using external beam irradiation (19 studies), low-dose brachytherapy (4 studies), or high-dose brachytherapy (1 study). Participants included in the review The participants were patients with diagnosed prostatecancer. Some trials selected the patients by the stage (B1, B2, C1, C2); others categorised the patients using a combination of risk factors (Gleason score and/or tumour stage and/or prostate-specific antigen). These were
Treatment of localised prostatecancer Treatment of localised prostatecancer Treatment of localised prostatecancer L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES). Treatment of localised prostatecancer (...) . Paris: L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) 2001: 4 Authors' objectives This report reviews the available evidence on the the efficacy and safety of treatment for localised prostatecancer. Authors' conclusions When a decision has been taken to treat localised prostatecancer, there is no formal evidence to support the superiority of either radical prostatectomy or localised external radiotherapy, or to justify the use of one form of treatment rather than another
Brachytherapy for localised prostatecancer Brachytherapy for localised prostatecancer Brachytherapy for localised prostatecancer Patterson J Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Patterson J. Brachytherapy for localised prostatecancer. London: Bazian Ltd (Editors), Wessex Institute for Health Research and Development, University of Southampton 2001 (...) : 9 Authors' objectives This study aims to assess the effects of brachytherapy versus other radiotherapy, radical prostatectomy, watchful waiting or drug treatments among men with localised prostatecancer. Authors' conclusions We found a lack of reliable evidence for effects of brachytherapy in men with localised non-metastatic prostatecancer. Particular difficulties exist in this therapeutic area, since the treatments are still evolving and may be used in many different combinations. Long
treatment of clinically localized prostatecancer. Comparisons will be made to evidence on outcomes and adverse effects of conformal external beam radiotherapy and nerve-sparing radical prostatectomy for clinically localized prostatecancer. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Cryosurgery; ProstaticNeoplasms Language Published English Country of organisation United States Address for correspondence BlueCross BlueShield Association, Technology Evaluation Center, 225 (...) Cryoablation for the primary treatment of clinically localized prostatecancer Cryoablation for the primary treatment of clinically localized prostatecancer Cryoablation for the primary treatment of clinically localized prostatecancer BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology
to assess the effects of cryotherapy compared with conventional treatments in men with prostatecancer. Authors' conclusions We found no evidence that cryosurgery improved clinical outcomes. Weak evidence from methodologically flawed case series suggested that cryosurgery may reduce biochemical and histological markers of disease from pre-intervention levels, although the clinical importance of such a reduction is unclear. We found no controlled trials comparing cryosurgery with other treatments (...) Cryotherapy for prostaticcancer Cryotherapy for prostaticcancer Cryotherapy for prostaticcancer Foster K N Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Foster K N. Cryotherapy for prostaticcancer. London: Bazian Ltd (Editors), Wessex Institute for Health Research and Development, University of Southampton 2001: 10 Authors' objectives This study aims